IRMD

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.

Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

IRadimed Corp revenue for the last quarter amounts to 21.20M USD, increased 15.69 % YoY.

IRadimed Corp. EPS for the last quarter amounts to 0.43 USD, increased 7.50 % YoY.

IRadimed Corp (IRMD) has 160 emplpoyees as of December 16 2025.

Today IRMD has the market capitalization of 1.23B USD.